Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 22791901.
- Also identified by DOI 10.1136/jnnp-2012-302548 and PMC identifier 4479493.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11. Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period. Both ligands displayed highly significant group discrimination and correlation of regional uptake. These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.
Medical subject headings
- Alzheimer Disease
- Aniline Compounds
- Ethylene Glycols
- Neuroimaging
- Plaque, Amyloid
- Positron-Emission Tomography
- Thiazoles